May 1, 1999Nephrology Dialysis Transplantation
Cardiovascular consequences of renal anaemia and erythropoietin therapy
Why the study?
Does recombinant human erythropoietin therapy improve cardiovascular outcomes and left ventricular geometry in patients with renal failure and chronic anaemia?
Population
Patients with renal failure and chronic anaemia
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support partial anemia correction in CKD to limit cardiac risk; leaves open optimal targets in advanced disease.
Structured PICO
Does recombinant human erythropoietin therapy improve cardiovascular outcomes and left ventricular geometry in patients with renal failure and chronic anaemia?
P
Population
Patients with renal failure and chronic anaemia
I
Intervention
Recombinant human erythropoietin (Epo) therapy
O
Outcome
Cardiac morbidity and mortality, and changes in left ventricular geometry
Partial correction of renal anaemia with erythropoietin improves cardiac oxygen supply and left ventricular geometry, suggesting early implementation may be necessary to maximize cardiovascular benefits.
Cite This Study
Kai‐Uwe Eckardt (1999) studied this question.